share_log

Forte Biosciences Secures $53M In Oversubscribed Private Placement To Advance FB102 Clinical Programs Across Autoimmune Indications, With Key Data Readouts Expected In 2025

Forte Biosciences Secures $53M In Oversubscribed Private Placement To Advance FB102 Clinical Programs Across Autoimmune Indications, With Key Data Readouts Expected In 2025

forte biosciences完成了1.3億美元的超額認購定向增發,以推進FB102臨床項目在自身免疫指標領域的發展,預計在2025年公佈關鍵數據結果。
Benzinga ·  2024/11/20 22:05

Forte Biosciences Secures $53M In Oversubscribed Private Placement To Advance FB102 Clinical Programs Across Autoimmune Indications, With Key Data Readouts Expected In 2025

forte biosciences在超額認購的定向增發中獲得5300萬美元,以推進FB102在自身免疫疾病領域的臨床項目,預計將於2025年發佈關鍵數據。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論